Published in PLoS One on May 30, 2012
Challenges and opportunities in estimating viral genetic diversity from next-generation sequencing data. Front Microbiol (2012) 1.89
Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues. World J Gastroenterol (2012) 0.90
Clinical application of estimating hepatitis B virus quasispecies complexity by massive sequencing: correlation between natural evolution and on-treatment evolution. PLoS One (2014) 0.84
Comparison of next-generation sequencing and clone-based sequencing in analysis of hepatitis B virus reverse transcriptase quasispecies heterogeneity. J Clin Microbiol (2013) 0.84
Quasispecies structure, cornerstone of hepatitis B virus infection: mass sequencing approach. World J Gastroenterol (2013) 0.84
Ultrasensitive amplification refractory mutation system real-time PCR (ARMS RT-PCR) assay for detection of minority hepatitis B virus-resistant strains in the era of personalized medicine. J Clin Microbiol (2013) 0.83
Extensive recombination due to heteroduplexes generates large amounts of artificial gene fragments during PCR. PLoS One (2014) 0.82
Association of preexisting drug-resistance mutations and treatment failure in hepatitis B patients. PLoS One (2013) 0.82
Quasispecies dynamics in main core epitopes of hepatitis B virus by ultra-deep-pyrosequencing. World J Gastroenterol (2012) 0.82
Implementation of Next-Generation Sequencing for Hepatitis B Virus Resistance Testing and Genotyping in a Clinical Microbiology Laboratory. J Clin Microbiol (2015) 0.81
Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy. Sci Rep (2015) 0.78
A deep sequencing reveals significant diversity among dominant variants and evolutionary dynamics of avian leukosis viruses in two infectious ecosystems. BMC Vet Res (2016) 0.77
Prevalence of WHO transmitted drug resistance mutations by deep sequencing in antiretroviral-naïve subjects in Hunan Province, China. PLoS One (2014) 0.77
rtM204Q may serve as a novel lamivudine-resistance-associated mutation of hepatitis B virus. PLoS One (2014) 0.77
HBV quasispecies composition in Lamivudine-failed chronic hepatitis B patients and its influence on virological response to Tenofovir-based rescue therapy. Sci Rep (2017) 0.75
Advanced molecular surveillance of hepatitis C virus. Viruses (2015) 0.75
Evidence of an Exponential Decay Pattern of the Hepatitis Delta Virus Evolution Rate and Fluctuations in Quasispecies Complexity in Long-Term Studies of Chronic Delta Infection. PLoS One (2016) 0.75
Analysis of Quasispecies of Avain Leukosis Virus Subgroup J Using Sanger and High-throughput Sequencing. Virol J (2016) 0.75
Genome sequencing in microfabricated high-density picolitre reactors. Nature (2005) 150.21
Accuracy and quality of massively parallel DNA pyrosequencing. Genome Biol (2007) 23.64
Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med (2004) 10.91
RNA virus mutations and fitness for survival. Annu Rev Microbiol (1997) 10.06
EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol (2008) 9.14
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci U S A (2008) 7.22
Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res (2007) 5.95
Vaccine-induced escape mutant of hepatitis B virus. Lancet (1990) 5.31
Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity. J Virol (1990) 4.57
Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis (2009) 4.48
Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A (1996) 4.02
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One (2009) 3.40
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology (2004) 3.19
Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis (2009) 3.08
Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology (2009) 3.05
Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother (2004) 2.67
Hepatitis B virus replication. World J Gastroenterol (2007) 2.30
Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol (2001) 2.14
Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol (2002) 1.81
Hepatitis B virus genetic variability and evolution. Virus Res (2007) 1.80
Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol (2008) 1.63
Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology (2002) 1.53
Nucleotide change of codon 182 in the surface gene of hepatitis B virus genotype C leading to truncated surface protein is associated with progression of liver diseases. J Hepatol (2011) 1.53
Transcomplementation of nucleotide priming and reverse transcription between independently expressed TP and RT domains of the hepatitis B virus reverse transcriptase. J Virol (1997) 1.50
Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother (2002) 1.45
The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology (2008) 1.41
Coexistence of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of "a" determinant variants. J Virol (2006) 1.39
Molecular evolution of hepatitis B virus over 25 years. J Virol (2006) 1.39
Inhibition of hepatitis B virus polymerase by entecavir. J Virol (2007) 1.32
Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int (2008) 1.29
Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol (2010) 1.27
Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol (2006) 1.27
A function essential to viral entry underlies the hepatitis B virus "a" determinant. J Virol (2009) 1.24
Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat (2006) 1.20
In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology (2000) 1.14
Analysis of hepatitis B genotype changes in chronic hepatitis B infection: Influence of antiviral therapy. J Hepatol (2008) 1.13
Advances in whole genome sequencing technology. Curr Pharm Biotechnol (2011) 1.12
Hepatitis B virus infection, its sequelae, and prevention by vaccination. Curr Opin Immunol (2011) 1.11
One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther (2006) 1.11
In vitro activity of hepatitis B virus polymerase: requirement for distinct metal ions and the viral epsilon stem-loop. J Gen Virol (1998) 1.09
Epitope specificity of Th0/Th2 CD4+ T-lymphocyte clones induced by vaccination with rHBsAg vaccine. Gastroenterology (1997) 1.04
Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery. Antiviral Res (2010) 0.99
Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients. J Viral Hepat (2007) 0.97
Ultra-deep pyrosequencing analysis of the hepatitis B virus preCore region and main catalytic motif of the viral polymerase in the same viral genome. Nucleic Acids Res (2011) 0.97
Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient. AIDS (2009) 0.90
Mosaic amino acid conservation in 3D-structures of surface protein and polymerase of hepatitis B virus. Virology (2007) 0.86
Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response. Antivir Ther (2008) 0.79
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med (2008) 7.22
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (2012) 6.93
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Biological and biomedical implications of the co-evolution of pathogens and their hosts. Nat Genet (2002) 4.42
The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol (2007) 4.09
Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med (2014) 4.09
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol (2005) 3.27
The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations. Am J Gastroenterol (2012) 3.11
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology (2010) 2.81
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med (2013) 2.68
Structure of foot-and-mouth disease virus RNA-dependent RNA polymerase and its complex with a template-primer RNA. J Biol Chem (2004) 2.48
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology (2013) 2.46
Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology (2010) 2.44
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol (2009) 2.39
Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol (2009) 2.39
Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J Hepatol (2013) 2.11
Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol (2003) 2.04
Hepatitis E virus epidemiology in industrialized countries. Emerg Infect Dis (2003) 2.03
Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol (2005) 2.00
Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol (2004) 1.97
Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol (2010) 1.96
Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology (2012) 1.89
Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology (2002) 1.89
Thrombocytopenia associated with chronic liver disease. J Hepatol (2008) 1.89
The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res (2009) 1.87
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut (2012) 1.86
Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. Am J Gastroenterol (2011) 1.80
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology (2010) 1.79
Validity of the Spanish version of the Chronic Liver Disease Questionnaire (CLDQ) as a standard outcome for quality of life assessment. Liver Transpl (2006) 1.77
Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology (2003) 1.76
A consensus view of protein dynamics. Proc Natl Acad Sci U S A (2007) 1.73
Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. J Hepatol (2009) 1.72
Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol (2012) 1.71
Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology (2011) 1.70
Functional and structural conservation of CBS domains from CLC chloride channels. J Physiol (2004) 1.67
Suppression of viral infectivity through lethal defection. Proc Natl Acad Sci U S A (2005) 1.62
Evolutionary transition toward defective RNAs that are infectious by complementation. J Virol (2004) 1.61
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol (2011) 1.59
Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol (2005) 1.58
Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus. J Virol (2003) 1.58
Effect of alternating passage on adaptation of sindbis virus to vertebrate and invertebrate cells. J Virol (2005) 1.57
Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J Virol (2006) 1.56
Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol (2004) 1.55
The structure of a protein primer-polymerase complex in the initiation of genome replication. EMBO J (2006) 1.54
Atrophy of mesenteric sympathetic innervation may contribute to splanchnic vasodilation in rat portal hypertension. Liver Int (2009) 1.48
TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis. Neurology (2013) 1.47
Blockage of the afferent sensitive pathway prevents sympathetic atrophy and hemodynamic alterations in rat portal hypertension. Liver Int (2012) 1.46
Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology (2003) 1.44
Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol (2010) 1.38
Sequential structures provide insights into the fidelity of RNA replication. Proc Natl Acad Sci U S A (2007) 1.37
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol (2011) 1.36
Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology (2006) 1.31
High mutation rates, bottlenecks, and robustness of RNA viral quasispecies. Gene (2005) 1.31
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol (2005) 1.30
Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol (2010) 1.27
Resistance of virus to extinction on bottleneck passages: study of a decaying and fluctuating pattern of fitness loss. Proc Natl Acad Sci U S A (2003) 1.27
Preextinction viral RNA can interfere with infectivity. J Virol (2004) 1.26
Predicting early mortality after acute variceal hemorrhage based on classification and regression tree analysis. Clin Gastroenterol Hepatol (2009) 1.24
Structural insights into replication initiation and elongation processes by the FMDV RNA-dependent RNA polymerase. Curr Opin Struct Biol (2009) 1.22
Hepatitis C virus (HCV)-specific T-cell responses among recombinant immunoblot assay-3-indeterminate blood donors: a confirmatory evidence of HCV exposure. Transfusion (2009) 1.21
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology (2012) 1.19
Duration and fitness dependence of quasispecies memory. J Mol Biol (2002) 1.18
Insights into RNA virus mutant spectrum and lethal mutagenesis events: replicative interference and complementation by multiple point mutants. J Mol Biol (2007) 1.17
Effectiveness of combined pharmacologic and ligation therapy in high-risk patients with acute esophageal variceal bleeding. Am J Gastroenterol (2011) 1.17
Lexical access in Catalan Signed Language (LSC) production. Cognition (2008) 1.16
Quality of life in cirrhosis is related to potentially treatable factors. Eur J Gastroenterol Hepatol (2010) 1.16
Similar and divergent effects of ppGpp and DksA deficiencies on transcription in Escherichia coli. J Bacteriol (2009) 1.16
Mutant viral polymerase in the transition of virus to error catastrophe identifies a critical site for RNA binding. J Mol Biol (2005) 1.13
Analysis of hepatitis B genotype changes in chronic hepatitis B infection: Influence of antiviral therapy. J Hepatol (2008) 1.13
MoDEL (Molecular Dynamics Extended Library): a database of atomistic molecular dynamics trajectories. Structure (2010) 1.12
Sporadic cases of acute autochthonous hepatitis E in Spain. J Hepatol (2004) 1.11
Usefulness of dried blood samples for quantification and molecular characterization of HBV-DNA. Hepatology (2004) 1.10
Evidence for quasispecies distributions in the human hepatitis A virus genome. Virology (2003) 1.10
Study of hepatitis B virus quasispecies by ultra-deep pyrosequencing: Resolving the nitty-gritty. Hepatology (2014) 1.09
PupasView: a visual tool for selecting suitable SNPs, with putative pathological effect in genes, for genotyping purposes. Nucleic Acids Res (2005) 1.08